Meptazinol: Difference between revisions

| IUPAC_name = (''RS'')-3-(3-ethylEthyl-1-methylazepan-3-yl)phenol

| image = Meptazinol_racemate2DCSDMeptazinol.svg

| width = 300150

| tradename = Meptid

| metabolism = The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours.

| elimination_half-life = Half-Lifelife (1.4–4 hours).

| excretion = The drug is rapidly metabolisedmetabolized to the [[glucuronide]], and mostly excreted in the urine.

| CAS_number_Ref = {{cascite|changedcorrect|??CAS}}

'''Meptazinol''' (trade name '''Meptid''') is an [[opioid]] [[analgesic]] developed by [[Wyeth]] in the 1970s.<ref>{{ cite patent | country = US | status = patent | number = 4197239 | title = Hexahydroazepine, Piperidine and Pyrrolidine Derivatives | gdate = 1980-04-08 | inventor = Cavalla JF, Shepherd RG, White AC | assign1 = Wyeth }}</ref> Indications for use in moderate to severe [[pain]], most commonly used to treat pain in [[obstetrics]] ([[childbirth]]).

Meptazinol is a 3-phenylazepane derivative, whereas the other phenazepanes like [[ethoheptazine]] and [[proheptazine]] are [[4-phenylazepane]]s.

A partial [[mu opioid receptor|µμ-opioid receptor]] [[agonist]], its mixed [[agonist]]/[[Receptor antagonist|antagonist]] activity affords it a lower risk of [[physical dependence|dependence]] and [[drug abuse|abuse]] than full µμ [[agonist]]s like [[morphine]]. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other [[opioid]]s such as [[morphine]], [[pentazocine]], or [[buprenorphine]].<ref name="Holmes 1985">{{ cite journal | author vauthors= Holmes B, Ward A | title = Meptazinol. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy | journal = Drugs | year = 1985 | volume = 30 | issue = 4 | pages = 285–312 | pmid = 2998723 | doi=10.2165/00003495-198530040-00001| s2cid = 208818234 }}</ref>

{{reflistReflist|30em}}